Johnson & Johnson Announces New Collaboration with Stop TB Partnership's Global Drug Facility to Enhance Access to Anti-TB

   Johnson & Johnson Announces New Collaboration with Stop TB Partnership's
          Global Drug Facility to Enhance Access to Anti-TB Compound

PR Newswire

NEW BRUNSWICK, N.J., April 29, 2014

NEW BRUNSWICK, N.J., April 29, 2014 /PRNewswire/ --Johnson & Johnson today
announced that its affiliate Janssen Pharmaceutica NV (Janssen) has entered
into a novel collaboration with the Stichting International Dispensary
Association  (IDA), a procurement agent for the Stop TB Partnership's Global
Drug Facility (GDF), to facilitate access to the Company's anti-tuberculosis
medicine. This public-private partnership was established by the newly formed
Janssen Global Public Health and is the latest in the Company's overall
efforts to improve public health.

Johnson & Johnson logo

"Multidrug-resistant tuberculosis is a complex public health problem," said
Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide
Chairman of Janssen. "We feel we have a responsibility to work together with
others in the TB community in order to tackle this challenge."

More than 130 low- and middle-income countries outside of the United States
will now be able to obtain this new anti-tuberculosis medicine through the
procurement processes of GDF and its agent, the IDA.

"We are committed to enhancing access to medicines through public-private
partnerships, differentiated pricing and responsible use and distribution of
medicines," said Adrian Thomas, M.D., Vice President of Global Market Access
at Janssen. "We believe that the collaboration with the Stop TB Partnership's
Global Drug Facility is a good example of how we can contribute to the
collective global access response for public health medicines."

Janssen has a long legacy of working to improve access to and appropriate use
of medicines for diseases of great unmet need, including HIV/AIDS,
tuberculosis, and other diseases impacting the developing world and emerging
markets.

"Our goal is to work with the GDF to facilitate access while ensuring
appropriate use of medicines," says Wim Parys, M.D., R&D Head, Global Public
Health at Janssen.

Johnson & Johnson is committed to advancing global health. Its family of
companies has launched and continues to support a variety of comprehensive
efforts toward strengthening the health of communities, improving maternal and
child health, and preventing the spread of infectious and preventable diseases
worldwide.For more information on Johnson & Johnson global health programs,
visit www.jnj.com.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to
addressing and solving the most important unmet medical needs of our time,
including oncology (e.g., multiple myeloma and prostate cancer), immunology
(e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis),
neuroscience (e.g., schizophrenia, dementia and pain), infectious disease
(e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and
metabolic diseases (e.g., diabetes).

Driven by our commitment to patients, we develop sustainable, integrated
healthcare solutions by working side-by-side with healthcare stakeholders,
based on partnerships of trust and transparency. To learn more, visit
www.janssen.com.

About Janssen Global Public Health

The Janssen Global Public Health (Janssen GPH) group complements the
groundbreaking science of the Janssen Pharmaceutical companies of Johnson &
Johnson with innovative strategies that improve access to medicines, foster
collaborations, and support public health solutions to sustainably advance
health care worldwide. Current areas of focus include multidrug-resistant
tuberculosis (MDR-TB); human immunodeficiency virus (HIV); elephantiasis and
river blindness; intestinal worms; and use of mobile technologies (mHealth) to
improve health outcomes.

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people
ofJohnson & Johnson. We embrace research and science ‒ bringing innovative
ideas, products and services to advance the health and well-being of people.
Our approximately 128,000 employees at more than 275Johnson &
Johnsonoperating companies work with partners in health care to touch the
lives of over a billion people every day, throughout the world.

Media Contacts:

Seema Kumar
Phone: (908) 405-1144
skumar10@its.jnj.com

Daniel De Schryver
Phone: +49 (173) 76 89 149
ddschryv@its.jnj.com

Investor Contacts:

Stan Panasewicz
Phone: (732) 524-2524

Louise Mehrotra
Phone: (732) 524-6491

Logo- http://photos.prnewswire.com/prnh/20140428/81226

SOURCE Johnson & Johnson

Website: http://www.jnj.com
 
Press spacebar to pause and continue. Press esc to stop.